A biotechnology company focused on developing gene therapies for severe genetic diseases and cancer.

bluebird

A biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs.

AVEO

A biotechnology company that focuses on the discovery, development, and commercialization of synthetic DNA immunotherapies for the treatment of cancers and infectious diseases.

Inovio

A biopharmaceutical company that develops and commercializes innovative monoclonal antibody-based therapeutics for the treatment of cancer.

MacroGenics Inc

A biotechnology company focused on developing innovative antibody-based therapeutics for the treatment of allergic and inflammatory diseases.

Allakos

Celldex is a clinical stage biotechnology company focused on developing transformative therapeutics for severe inflammatory, allergic, autoimmune, and other devastating diseases.

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Celldex Therapeutics, Inc.

industry_trends_dossier

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

signals

swot_dossier

news_advanced

news_impact_assignment_basic

news_impact_assignment_advanced

news_processing_basic

news_processing_advanced

peers

valuation

customer_profile

news_basic

NASDAQ:CLDX

Celldex

Last Close

40.86

03/05 20:00

Market Cap

2.00B

Beta: 2.11

Volume Today

583.81K

Avg: 647.39K

PE Ratio

−15.31

PFCF: −20.78